In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate

BACKGROUND: HIV-1 integrase (IN) is an emerging drug target, as IN strand transfer inhibitors (INSTIs) are proving potent antiretroviral agents in clinical trials. One credible theory sees INSTIs as docking at the cellular (acceptor) DNA-binding site after IN forms a transitional complex with viral...

Descripción completa

Detalles Bibliográficos
Autor principal: Savarino, Andrea
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1847836/
https://www.ncbi.nlm.nih.gov/pubmed/17374162
http://dx.doi.org/10.1186/1742-4690-4-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1847836/
https://www.ncbi.nlm.nih.gov/pubmed/17374162
http://dx.doi.org/10.1186/1742-4690-4-21

Ejemplares similares